| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $265.1M | +35.0% |
| SG&A Expense | $57.3M | -23.7% |
| Operating Income | -$322.4M | -18.8% |
| Net Income | -$320.0M | -18.6% |
| EPS (Basic) | -$5.06 | -1.0% |
| EPS (Diluted) | -$5.06 | -1.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $87.2M | -42.9% |
| Short-term Investments | $192.6M | -29.1% |
| Current Assets | $308.8M | -31.6% |
| Total Assets | $386.4M | -27.7% |
| Current Liabilities | $30.0M | -25.4% |
| Total Liabilities | $76.0M | -15.0% |
| Stockholders' Equity | $310.4M | -30.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$280.0M | -34.7% |
| Capital Expenditures | $8.3M | -74.9% |
| Investing Cash Flow | $71.7M | -50.0% |
| Financing Cash Flow | $141.9M | +1282.9% |
| Free Cash Flow | -$288.3M | -19.6% |